| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $4.71B | -10.6% |
| Gross profit | $2.15B | — |
| Operating income | $0.09B | — |
| Net income | $-0.31B | -201.0% |
| Gross margin | 45.7% | Net margin -6.6% |
| Revenue Q/Q | -10.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| Interventional | $1.36B | 28.8% |
| Connected Care | $1.12B | 23.8% |
| US | $0.96B | 20.5% |
| Non Us | $0.68B | 14.5% |
| Bio Pharma Systems | $0.59B | 12.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $2.56B | 54.3% |
| R&D | $0.25B | 5.3% |
| SG&A | $1.21B | 25.7% |
| Tax & other | $0.40B | 8.6% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
BRK.B ・ BBY ・ TECH ・ BIIB ・ BLK ・ BX ・ XYZ ・ BNY ・ BA ・ BKNG ・ BSX ・ BMY
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies